Author

Aki Linden

Observed name: A. Linden

Institution: Santhera Pharmaceuticals (Switzerland)

Observed institution: Santhera Pharmaceuticals (Switzerland)

ORCID: 0009-0005-1081-1071

Observed ORCID: 0009-0005-1081-1071

OpenAlex ID: A5081465993

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Journal of Neurology · 4

Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy

2026 · Jean K. Mah, Hernan D. Gonorazky, et al. · Neurology · 1

Plain language summary of vamorolone for boys with Duchenne muscular dystrophy age 7 to less than 18 years

2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Figshare

Plain language summary of vamorolone for boys with Duchenne muscular dystrophy age 7 to less than 18 years

2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Future Neurology

2.60P Decoupling growth and loss of ambulation in Duchenne muscular dystrophy (DMD): Long-term outcomes with Vamorolone

2026 · Giovanni Baranello, Erik H. Niks, et al. · Neuromuscular Disorders

681VPPharmacokinetics, initial safety and efficacy of vamorolone in 2–<4-year-old boys with Duchenne muscular dystrophy

2025 · J. Mah, H. Gonorazky, et al. · Neuromuscular Disorders

P.133 Daily regimens of prednisone, deflazacort and vamorolone improve motor function similarly in patients with Duchenne muscular dystrophy

2022 · C. McDonald, E. Henricson, et al. · Neuromuscular Disorders

Works count: 7

Citation count: 5

H-index: 1

I10-index: